Tuberculosis Treatment The Search For New Drugs
Download Tuberculosis Treatment The Search For New Drugs full books in PDF, epub, and Kindle. Read online free Tuberculosis Treatment The Search For New Drugs ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : Marcus V.N. de Souza |
| Publisher | : Bentham Science Publishers |
| Total Pages | : 236 |
| Release | : 2013-11-21 |
| Genre | : Medical |
| ISBN | : 1608057887 |
Despite the high impact on human health caused by Tuberculosis (TB) infections worldwide, nearly 45 years have passed since a novel drug was introduced for its treatment. As MDR-TB and XDR-TB cases rise globally new strategies and drugs are desperately needed to address this problem. Tuberculosis Treatment: The Search For New Drugs covers a wide range of topics about TB drug discovery. The e-book begins with historical information about Tuberculosis discovery and treatment and explores modern treatment strategies, formulations (synthetic and natural) and class of compounds. The extraction of important drugs from various sources is also covered in separate chapters along with information about promising drugs undergoing clinical testing. The e-book is a useful reference for readers interested in learning about the array of pharmaceuticals discovered and used to combat Mycobacterium tuberculosis infections.
| Author | : Megan Durham |
| Publisher | : Hayle Medical |
| Total Pages | : 0 |
| Release | : 2023-09-26 |
| Genre | : Health & Fitness |
| ISBN | : 9781646475254 |
Tuberculosis (TB) refers to a type of infectious disease generally caused by Mycobacterium tuberculosis. Lungs are the primary target of this disease, but it can also affect the other parts of the body. It can be treated with a combination of antibacterial medications. However, the evolution of drug-resistant tuberculosis necessitates the development of effective, novel and safe drug regimens. Drug discovery and development is a difficult, expensive and time-consuming process. One of the popular frameworks used in drug discovery is model-informed drug discovery and development (MID3). It aims to provide an informative prediction of drug efficacy and exposure in people for choosing innovative anti-tuberculosis drug combinations. This book is compiled in such a manner, that it will provide in-depth knowledge about drug discovery for treating tuberculosis. Those with an interest in this area of pharmaceutical science would find it helpful.
| Author | : World Health Organization |
| Publisher | : |
| Total Pages | : 60 |
| Release | : 1993 |
| Genre | : Medical |
| ISBN | : |
| Author | : King K. Holmes |
| Publisher | : World Bank Publications |
| Total Pages | : 1027 |
| Release | : 2017-11-06 |
| Genre | : Medical |
| ISBN | : 1464805253 |
Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.
| Author | : World Health Organization |
| Publisher | : |
| Total Pages | : 0 |
| Release | : 2015-04-20 |
| Genre | : Medical |
| ISBN | : 9789241501583 |
This 2011 update of Guidelines for the programmatic management of drug-resistant tuberculosis is intended as a tool for use by public health professionals working in response to the Sixty-second World Health Assembly's resolution on prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Resolution WHA62.15, adopted in 2009, calls on Member States to develop a comprehensive framework for the management and care of patients with drug-resistant TB. The recommendations contained in these guidelines address the most topical questions concerning the programmatic management of drug-resistant TB: case-finding, multidrug resistance, treatment regimens, monitoring the response to treatment, and selecting models of care. The guidelines primarily target staff and medical practitioners working in TB treatment and control, and partners and organizations providing technical and financial support for care of drug-resistant TB in settings where resources are limited.
| Author | : World Health Organization |
| Publisher | : |
| Total Pages | : 0 |
| Release | : 2016 |
| Genre | : Medical |
| ISBN | : 9789241565394 |
This global tuberculosis report is the first to be produced in the era of the SDGs and the End TB Strategy. It provides an assessment of the TB epidemic and progress in TB diagnosis, treatment, and prevention efforts as well as an overview of TB-specific financing and research. It also discusses the broader agenda of universal health coverage, social protection, and other SDGs that have an impact on health. Data was available for 202 countries and territories that account for over 99% of the world's population and TB cases.
| Author | : Giovanna Riccardi |
| Publisher | : MDPI |
| Total Pages | : 296 |
| Release | : 2020-11-24 |
| Genre | : Science |
| ISBN | : 3039432362 |
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main causes of death due to a single pathogen. Standard anti-TB therapy includes four first-line antibiotics that should be administered for at least six months. However, in the case of multi- and extensively drug-resistant TB, second-line medications must be used and these frequently cause severe side effects resulting in poor compliance. Developing new anti-TB drug candidates is therefore of outmost importance. In this Special Issue dedicated to Tuberculosis Drug Discovery and Development, we present the main and latest achievements in the fields of drug and target discovery, host-directed therapy, anti-virulence drugs, and describe the development of two advanced compounds: macozinone and delpazolid. In addition, this Special Issue provides an historical perspective focused on Carlo Forlanini, the inventor of pneumothorax for TB treatment, and includes an overview of the state-of-the-art technologies which are being exploited nowadays in TB drug development. Finally, a summary of TB vaccines that are either approved or undergoing clinical trials concludes the Special Issue.
| Author | : Russian Academy of Medical Sciences |
| Publisher | : National Academies Press |
| Total Pages | : 158 |
| Release | : 2011-07-07 |
| Genre | : Medical |
| ISBN | : 0309225051 |
An estimated 2 billion people, one third of the global population, are infected with Mycobacterium tuberculosis, the bacterium that causes tuberculosis. Spread through the air, this infectious disease killed 1.7 million in 2009, and is the leading killer of people with HIV. Tuberculosis (TB) is also a disease of poverty-the vast majority of tuberculosis deaths occur in the developing world. Exacerbating the devastation caused by TB is the growing threat of drug-resistant forms of the disease in many parts of the world. Drug-resistant tuberculosis presents a number of significant challenges in terms of controlling its spread, diagnosing patients quickly and accurately, and using drugs to treat patients effectively. In Russia in recent decades, the rise of these strains of TB, resistant to standard antibiotic treatment, has been exacerbated by the occurrence of social, political, and economic upheavals. The Institute of Medicine (IOM) Forum on Drug Discovery, Development, and Translation, in conjunction with the Russian Academy of Medical Sciences held a workshop to discuss ways to fight the growing threat of drug-resistant TB. The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective: Summary of a Joint Workshop presents information from experts on the nature of this threat and how it can be addressed by exploring various treatment and diagnostic options.
| Author | : Peter R. Donald |
| Publisher | : Karger Medical and Scientific Publishers |
| Total Pages | : 262 |
| Release | : 2011 |
| Genre | : Medical |
| ISBN | : 3805596278 |
Tuberculosis (TB) remains one of the major infectious diseases of mankind although drugs for its treatment have been available for nearly 60 years. The standard short-course 6-month regimen used since about 1980 has helped to save millions of lives, but co-infection with HIV has had a devastating effect on the epidemic, and multidrug-resistant TB is a growing problem, particularly in communities with a high incidence of HIV. Following the declaration by the WHO in the early 1990s that TB was a 'global health emergency', interest in TB research and the development of new drugs has increased significantly. This volume reviews anti-TB chemotherapy with the emphasis on the actions and pharmacology of existing drugs and the development and evaluation of new agents. A close look is taken at new research regarding our existing drugs by some of the best-known specialists in the field, and historical aspects of these agents are reviewed from a modern perspective. The prospects for the introduction of new drugs and different approaches of how to assess them in adults and in children are discussed in detail. Several papers address the problems associated with drug resistance, its spread and diagnosis. Compiled by two editors from Cape Town, which has a particularly high incidence of TB and is a centre of tuberculosis research, this publication is an indispensable reference for anyone involved in the management of TB either as a researcher, clinician or administrator, and those working in drug development.
| Author | : Institute of Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 288 |
| Release | : 2000-08-31 |
| Genre | : Medical |
| ISBN | : 0309171946 |
Tuberculosis emerged as an epidemic in the 1600s, began to decline as sanitation improved in the 19th century, and retreated further when effective therapy was developed in the 1950s. TB was virtually forgotten until a recent resurgence in the U.S. and around the worldâ€"ominously, in forms resistant to commonly used medicines. What must the nation do to eliminate TB? The distinguished committee from the Institute of Medicine offers recommendations in the key areas of epidemiology and prevention, diagnosis and treatment, funding and organization of public initiatives, and the U.S. role worldwide. The panel also focuses on how to mobilize policy makers and the public to effective action. The book provides important background on the pathology of tuberculosis, its history and status in the U.S., and the public and private response. The committee explains how the U.S. can act with both self-interest and humanitarianism in addressing the worldwide incidence of TB.
